The AMNOG-Monitor provides all relevant information on early benefit assessment and price negotiations, updated daily. A solid foundation for Market Access, HTA, Medical, Business Development, and Pricing.
16. October 2026
Fayuvi (rebisufligene etisparvovec) from Ultragenyx
A gene therapy for the treatment of mucopolysaccharidosis type IIIA (Sanfilippo syndrome type A).
Assessor: Austria; co-assessor: Hungary.
Lirafugratinib (lirafugratinib) from Elevar Therapeutics
For the …
11. October 2026
The discontinuations of Joint Clinical Assessments (JCA) under the EU-HTA to date can be traced back to different regulatory and methodological causes.
02. October 2026
Berlin, 2 October 2026
Today, the Federal Joint Committee (GBA) adapted Annex XIIa of its Pharmaceuticals Directive to the changes resulting from the Statutory Health Insurance Contribution Rate Stabilisation Act …
Key data from all AMNOG decisions, summarized in a compact and structured format.
Analyze your own research questions by filtering across more than 120 parameters.
Fast, quality-assured analysis of original documents such as dossiers, G-BA decisions, arbitration rulings, and clinical trials.
Price trends for all AMNOG drugs at PZN level and for annual therapy costs. Tracking of all appropriate comparator therapies (ZVT) and their weighting (on request).
EU dossiers and JCAs will be integrated into the AMNOG-Monitor as soon as the first ones become available.
Export analysis results to Excel, PowerPoint, or Word with links back to the AMNOG-Monitor. Save standard queries for price changes or new indications using bookmarks.
